Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

M. McKean, M. Barve, D. Hong, A. Parikh, E. Rosen, J. Yang, R. Picard, J. Yi, L. Brail, D. Vecchio, T. Meniawy, T. John, J. Wang

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)S34
JournalEuropean Journal of Cancer
Issue numberSupplement 1
Publication statusPublished - Oct 2022

Cite this